Login to Your Account



Clinic Roundup


Friday, March 16, 2012

• Cytomedix Inc., of Gaithersburg, Md., said data from a randomized Phase I trial of ALD-201 in ischemic heart failure were published in the online edition of the American Heart Journal. The study enrolled 20 heart failure patients with no treatment options, evaluating safety as the primary endpoint.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription